$CLRB
Cellectar Biosciences, Inc.

2024 Q1 Form 10-K Financial Statement

#000141057824000307 Filed on March 27, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.624M $4.611M $10.75M
YoY Change 125.41% 134.23% 12.04%
% of Gross Profit
Research & Development $7.378M $7.936M $28.21M
YoY Change 10.88% 45.52% 46.78%
% of Gross Profit
Depreciation & Amortization $88.49K $72.38K $192.4K
YoY Change 107.93% 89.68% 29.99%
% of Gross Profit
Operating Expenses $7.378M $12.55M $38.96M
YoY Change 10.88% 69.05% 102.71%
Operating Profit -$12.00M -$38.96M
YoY Change 37.86% 35.22%
Interest Expense $319.8K $5.039M $917.2K
YoY Change 157.87% 3317.81% 501.33%
% of Operating Profit
Other Income/Expense, Net -$9.580M $917.1K
YoY Change -7823.81% 501.33%
Pretax Income -$21.58M -$7.509M -$38.04M
YoY Change 151.5% 3.21% 32.73%
Income Tax -$60.00K -$60.00K
% Of Pretax Income
Net Earnings -$21.58M -$7.449M -$37.98M
YoY Change 151.5% 3.24% 32.8%
Net Earnings / Revenue
Basic Earnings Per Share -$0.74 -$3.11
Diluted Earnings Per Share -$0.74 -$0.49 -$3.11
COMMON SHARES
Basic Shares Outstanding 32.26M 12.29M 12.22M
Diluted Shares Outstanding 29.35M 12.22M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.03M $9.565M $9.565M
YoY Change 215.64% -51.85% -51.85%
Cash & Equivalents $40.03M $9.565M $9.565M
Short-Term Investments
Other Short-Term Assets $1.337M $888.2K $888.2K
YoY Change 14.9% 33.92% 33.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $41.37M $10.45M $10.45M
YoY Change 198.77% -49.08% -49.08%
LONG-TERM ASSETS
Property, Plant & Equipment $1.023M $1.593M $1.593M
YoY Change 172.13% 280.42% 62.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.214K $29.78K $29.78K
YoY Change 0.0% 379.24% -63.33%
Total Long-Term Assets $1.540M $1.622M $1.622M
YoY Change 55.25% 53.03% 53.03%
TOTAL ASSETS
Total Short-Term Assets $41.37M $10.45M $10.45M
Total Long-Term Assets $1.540M $1.622M $1.622M
Total Assets $42.91M $12.08M $12.08M
YoY Change 189.17% -44.07% -44.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.394M $9.179M $6.872M
YoY Change 7.09% 258.82% 63.79%
Accrued Expenses $73.99K $58.98K $2.366M
YoY Change 44.77% 15.99% 77.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.27M $12.94M $12.94M
YoY Change 133.88% 133.98% 133.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $474.4K $494.0K $494.0K
YoY Change -13.49% -10.67% -10.67%
Total Long-Term Liabilities $474.4K $494.0K $494.0K
YoY Change -13.49% -10.67% -10.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.27M $12.94M $12.94M
Total Long-Term Liabilities $474.4K $494.0K $494.0K
Total Liabilities $16.74M $13.43M $13.43M
YoY Change 123.11% 120.83% 120.83%
SHAREHOLDERS EQUITY
Retained Earnings -$239.1M -$217.5M
YoY Change 21.16%
Common Stock $332.00 $207.00
YoY Change 242.27% 120.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.17M -$1.356M -$1.356M
YoY Change
Total Liabilities & Shareholders Equity $42.91M $12.08M $12.08M
YoY Change 189.17% -44.07% -44.07%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$21.58M -$7.449M -$37.98M
YoY Change 151.5% 3.24% 32.8%
Depreciation, Depletion And Amortization $88.49K $72.38K $192.4K
YoY Change 107.93% 89.68% 29.99%
Cash From Operating Activities -$13.36M -$9.597M -$32.38M
YoY Change 86.0% 29.48% 28.37%
INVESTING ACTIVITIES
Capital Expenditures $21.63K $264.0K $864.0K
YoY Change 124.05% 282.37%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$21.63K -$264.0K -$864.0K
YoY Change 124.05% 282.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $22.94M
YoY Change 138.69%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 43.85M 439.6K 22.94M
YoY Change 1461648800.0% -95.43% 138.69%
NET CHANGE
Cash From Operating Activities -13.36M -9.597M -32.38M
Cash From Investing Activities -21.63K -264.0K -864.0K
Cash From Financing Activities 43.85M 439.6K 22.94M
Net Change In Cash 30.47M -9.421M -10.30M
YoY Change -524.1% -552.72% -34.96%
FREE CASH FLOW
Cash From Operating Activities -$13.36M -$9.597M -$32.38M
Capital Expenditures $21.63K $264.0K $864.0K
Free Cash Flow -$13.38M -$9.861M -$33.24M
YoY Change 86.3% 30.96% 30.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001279704
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9385272
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20744110
CY2022Q2 clrb Stockholder Equity Note Stock Split Conversion Ratio1
StockholderEquityNoteStockSplitConversionRatio1
0.10
CY2022Q2 clrb Stockholder Equity Note Stock Split Conversion Ratio1
StockholderEquityNoteStockSplitConversionRatio1
0.10
CY2023 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2022Q3 us-gaap Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration
GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#CostsAndExpenses
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-36598
CY2023 dei Entity Registrant Name
EntityRegistrantName
CELLECTAR BIOSCIENCES, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3321804
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Campus Drive
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
CY2023 dei City Area Code
CityAreaCode
608
CY2023 dei Local Phone Number
LocalPhoneNumber
441-8120
CY2023 dei Security12b Title
Security12bTitle
Common stock, par value $0.00001
CY2023 dei Trading Symbol
TradingSymbol
CLRB
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
18922339
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32260510
CY2023 dei Auditor Firm
AuditorFirmId
23
CY2023 dei Auditor Name
AuditorName
Baker Tilly US, LLP
CY2023 dei Auditor Location
AuditorLocation
Madison, Wisconsin
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9564988
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19866358
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
888225
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
663243
CY2023Q4 us-gaap Assets Current
AssetsCurrent
10453213
CY2022Q4 us-gaap Assets Current
AssetsCurrent
20529601
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1090304
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
418641
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
502283
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
560334
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
23566
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
75000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6214
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6214
CY2023Q4 us-gaap Assets
Assets
12075580
CY2022Q4 us-gaap Assets
Assets
21589790
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9178645
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5478443
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3700000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
58979
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
50847
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12937624
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5529290
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
494003
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
552981
CY2023Q4 us-gaap Liabilities
Liabilities
13431627
CY2022Q4 us-gaap Liabilities
Liabilities
6082271
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20744110
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20744110
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9385272
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9385272
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
207
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
94
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
210066630
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
193624445
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217482539
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179499043
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1356047
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15507519
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12075580
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21589790
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28211460
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19219603
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10749183
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9594170
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
38960643
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
28813773
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-38960643
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-28813773
CY2023 clrb Warrant Issuance Expense From Nonoperating
WarrantIssuanceExpenseFromNonoperating
470000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1000000
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
387147
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
152519
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
917147
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
152519
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38043496
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28661254
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-60000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-60000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-37983496
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28601254
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.11
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.11
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.05
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.05
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12221571
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12221571
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7055665
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7055665
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33045154
CY2022 clrb Stock Issued During Period Value Pre Funded Warrants And Warrants Net Of Issuance Costs
StockIssuedDuringPeriodValuePreFundedWarrantsAndWarrantsNetOfIssuanceCosts
9610655
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1452964
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28601254
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15507519
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2410288
CY2023 clrb Exercise Of Warrants Into Common Shares Value
ExerciseOfWarrantsIntoCommonSharesValue
789642
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17920000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-37983496
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1356047
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-37983496
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28601254
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
192375
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
148435
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
2410288
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1452964
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3386
CY2023 clrb Warrant Issuance Expense Operating Activities
WarrantIssuanceExpenseOperatingActivities
470000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1000000
CY2023 clrb Non Cash Lease Expense
NonCashLeaseExpense
58051
CY2022 clrb Non Cash Lease Expense
NonCashLeaseExpense
90432
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
173548
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-204242
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3700202
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1623529
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-50846
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-144035
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32376974
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25222301
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
864038
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
225971
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-864038
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-225971
CY2023 clrb Proceeds From Issuance Of Preferred Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfPreferredStockAndWarrantsNetOfIssuanceCost
-22150000
CY2022 clrb Proceeds From Issuance Of Preferred Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfPreferredStockAndWarrantsNetOfIssuanceCost
-9610655
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
789642
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22939642
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9610655
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10301370
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15837617
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19866358
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35703975
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9564988
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19866358
CY2023 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
13242368
CY2023 clrb Conversion Of Mezzanine Equity To Permanent Equity
ConversionOfMezzanineEquityToPermanentEquity
17920000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217483000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-37983000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<span style="font-style:italic;font-weight:bold;">Use of Estimates</span> — The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities and expenses and disclosure of contingent assets and liabilities. On an on-going basis, management evaluates its estimates including those related to potential accrued liabilities, valuation of warrant and equity-based instruments, and share-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from those estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
CY2022 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2023 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span> — Financial instruments that subject the Company to credit risk consist of cash and cash equivalents on deposit with financial institutions. The Company’s excess cash as of December 31, 2023 and 2022 is on deposit in interest-bearing accounts with well-established financial institutions. At times, such amounts may exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits. As of December 31, 2023, uninsured cash balances totaled approximately $9,123,000.</p>
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
9123000
CY2023 clrb Proceeds From Cancer Treatment
ProceedsFromCancerTreatment
2000000.0
CY2023 clrb Proceeds From Research And Development
ProceedsFromResearchAndDevelopment
1759000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1975213
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1111175
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
884909
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
692534
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1090304
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
418641
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
192000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
148000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2069000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
916000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5620000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2558000
CY2023Q4 clrb Clinical Trial Costs Current
ClinicalTrialCostsCurrent
1252000
CY2022Q4 clrb Clinical Trial Costs Current
ClinicalTrialCostsCurrent
1637000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
153000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
359000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
85000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9179000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5478000
CY2023 clrb Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
177877
CY2022 clrb Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
28002379
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1617000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
440250
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.35
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.49
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1647355
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
712431
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
11.13
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.81
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
19.92
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
5.25
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
1.41
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
7.33
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
308144
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
135986
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
540223
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
343996
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
5.25
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.20
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2205192
CY2023 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
1330233
CY2023 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
775193
CY2023 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
99766
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-60000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-60000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-60000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-60000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-12233641
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-7800350
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2764638
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2633146
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-14998279
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-10433496
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
14998279
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
10433496
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-60000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-60000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
39914591
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
35958687
CY2023Q4 clrb Deferred Tax Assets Tax Credit Carry Forwards Domestic Research And Development
DeferredTaxAssetsTaxCreditCarryForwardsDomesticResearchAndDevelopment
15868907
CY2022Q4 clrb Deferred Tax Assets Tax Credit Carry Forwards Domestic Research And Development
DeferredTaxAssetsTaxCreditCarryForwardsDomesticResearchAndDevelopment
11484209
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
7626490
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
6186679
CY2023Q4 clrb Deferred Tax Assets Deferred Expense Capitalized Research And Development Cost
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost
20203493
CY2022Q4 clrb Deferred Tax Assets Deferred Expense Capitalized Research And Development Cost
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost
15820893
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3710609
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3186702
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
754180
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
443693
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
88078270
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
73080863
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
156626
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
157498
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
156626
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
157498
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
87921644
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
72923365
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
87921644
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
72923365
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0781
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0935
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0020
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0001
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.1150
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.0657
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3640
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0032
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0031
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0018
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0020
CY2023 clrb Net Operating Loss Carryforwards Expiration Period
NetOperatingLossCarryforwardsExpirationPeriod
80,001,000
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
502000
CY2023Q4 clrb Research And Development And Investment Tax Credits
ResearchAndDevelopmentAndInvestmentTaxCredits
13000
CY2023 clrb Research And Development And Investment Tax Credits Expiration Period
ResearchAndDevelopmentAndInvestmentTaxCreditsExpirationPeriod
2023
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33979239
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7571847
CY2023Q4 us-gaap Area Of Land
AreaOfLand
3983
CY2023Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P60M
CY2023 us-gaap Payments For Rent
PaymentsForRent
11800
CY2023 clrb Increase In Percentage Of Rent
IncreaseInPercentageOfRent
0.02
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.14
CY2018Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
132000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
146000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
150000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
153000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
155000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
53000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
789000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
236000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
553000

Files In Submission

Name View Source Status
0001410578-24-000307-index-headers.html Edgar Link pending
0001410578-24-000307-index.html Edgar Link pending
0001410578-24-000307.txt Edgar Link pending
0001410578-24-000307-xbrl.zip Edgar Link pending
clrb-20231231.xsd Edgar Link pending
clrb-20231231x10k.htm Edgar Link pending
clrb-20231231xex21d1.htm Edgar Link pending
clrb-20231231xex23d1.htm Edgar Link pending
clrb-20231231xex31d1.htm Edgar Link pending
clrb-20231231xex31d2.htm Edgar Link pending
clrb-20231231xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
clrb-20231231_cal.xml Edgar Link unprocessable
clrb-20231231_def.xml Edgar Link unprocessable
clrb-20231231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
clrb-20231231x10k_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
clrb-20231231_pre.xml Edgar Link unprocessable